摘要
目的 :探讨血管紧张素转换酶抑制剂 (ACEI)对体内抗氧化状态的影响。方法 :采用分光光度计测定红细胞超氧化物歧化酶 (SOD)活力和血浆总抗氧化能力 (TAC)。观察了 6 7例充血性心力衰竭 (CHF)患者口服培哚普利后血浆TAC和SOD活力的改变 ,并与依那普利进行比较。结果 :两治疗组CHF患者基础红细胞SOD活力、血浆TAC水平低于健康对照组 (P <0 .0 1) ;服药后 4周 ,依那普利组和培哚普利组红细胞SOD活力、血浆TAC水平升高 (P <0 .0 5 ) ,8周后进一步升高 (P <0 .0 1)。结论 :CHF患者的抗氧化能力低下 ,依那普利和培哚普利均能提高CHF患者的抗氧化能力 。
Objective:This study investigate the changes of plasma TAC level and erythrocyte SOD activity in patients with congestive heart failure (CHF) after administration of angiotensin converting-enzyme inhibitor(ACEI).Methods:Plasma TAC level and erythrocyte SOD activity were measured by using spectrophotometer.Results:The basic levels of plasma TAC and erythrocyte SOD activity in patients with CHF were lower than that in control group(P< 0.01). Plasma TAC and erythrocyte SOD activity in perindopril group and enalaprol group increased significantly 4 week after administration(P< 0.05) and rose more remarkably 8 week after administration(P< 0.01). Conclusion:These patients with CHF have lower antioxidative ability. ACEIs such as Perindopril and Enalaprol can promote the antioxidative ability and play a beneficial role in protecting from deterioration of CHF.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2003年第6期333-335,共3页
Journal of Clinical Cardiology
